|Last Price||Today's Change||52-Week Range||Trading Volume|
|56.88||-0.96 (-1.66%)||52.49 - 63.62||11.7 million|
Market data as of 4:03PM 04/17/15. Quotes are delayed by at least 15 min.
KEYTRUDA® (pembrolizumab), Merck’s Anti-PD-1 Therapy, Demonstrates Superior Survival, Progression Free Survival and Overall Response Rate Compared to Ipilimumab an Anti-CTLA-4 Therapy...
04/19/2015 8:30 AM ET